Comparative Diagnostic and Prognostic Performances of the Hematoxylin-eosin and Phospho-histone H3 Mitotic Count and Ki-67 Index in Adrenocortical Carcinoma
Overview
Authors
Affiliations
Mitotic count on hematoxylin and eosin slides is a fundamental morphological criterion in the diagnosis and grading of adrenocortical carcinoma in any scoring system employed. Moreover, it is the unique term strongly associated with patient's prognosis. Phospho-histone H3 is a mitosis-specific antibody, which was already proven to facilitate mitotic count in melanoma and other tumors. Therefore, a study was designed to assess the diagnostic and prognostic role of phospho-histone H3 in 52 adrenocortical carcinomas, comparing manual and computerized count to standard manual hematoxylin- and eosin-based method and Ki-67 index. Manual hematoxylin and eosin and phospho-histone H3 mitotic counts were highly correlated (r=0.9077, P<0.0001), better than computer-assisted phospho-histone H3 evaluations, and had an excellent inter-observer reproducibility at Bland-Altman analysis. Three of 15 cases having <5 mitotic figures per 50 high-power fields by standard count on hematoxylin and eosin gained the mitotic figure point of Weiss Score after a manual count on phospho-histone H3 slides. Traditional mitotic count confirmed to be a strong predictor of overall survival (P=0.0043), better than phospho-histone H3-based evaluation (P=0.051), but not as strong as the Ki-67 index (P<0.0001). The latter further segregated adrenocortical carcinomas into three prognostic groups, stratifying cases by low (<20%), intermediate (20-50%), and high (>50%) Ki-67 values. We conclude that (a) phospho-histone H3 staining is a useful diagnostic complementary tool to standard hematoxylin and eosin mitotic count, enabling optimal mitotic figure evaluation (including atypical mitotic figures) even in adrenocortical carcinomas with a low mitotic index and with a very high reproducibility; (b) Ki-67 proved to be the best prognostic indicator of overall survival, being superior to the mitotic index, irrespective of the method (standard on hematoxylin and eosin or phospho-histone H3-based) used to count mitotic figures.
Gan W, Han X, Gong Y, Yang Y, Wang C, Zhang Z Diagn Pathol. 2024; 19(1):71.
PMID: 38802933 PMC: 11131238. DOI: 10.1186/s13000-024-01496-z.
Kar A, Sable M, A A, Jena S, Tripathy P, Gaikwad M Cureus. 2023; 15(6):e41159.
PMID: 37525760 PMC: 10387164. DOI: 10.7759/cureus.41159.
Adjuvant therapy in adrenocortical carcinoma: prognostic factors and treatment options.
Al-Ward R, Zsembery C, Habra M Endocr Oncol. 2023; 2(1):R90-R101.
PMID: 37435451 PMC: 10259337. DOI: 10.1530/EO-22-0050.
Genomic Landscape of Meningiomas.
Wang J, Nassiri F, Mawrin C, Zadeh G Adv Exp Med Biol. 2023; 1416:137-158.
PMID: 37432625 DOI: 10.1007/978-3-031-29750-2_11.
La Rosa S Endocr Pathol. 2023; 34(1):79-97.
PMID: 36797453 PMC: 10011307. DOI: 10.1007/s12022-023-09755-3.